In a murine model of SLE, CLN-978 treatment led to a reduction in circulating B cells, levels of anti-dsDNA IgG, and IgG deposition in the kidney, indicating a disease-modifying effect in both ...

Kernal has been awarded up to $48M funding to accelerate the development of KR-402, a next-generation in vivo CAR T-cell ...

Results from pre-clinical studies demonstrate immunomodulatory activity of QEL-005 across multiple immune cell lineages involved in complex autoimmune inflammation, including B cells, T cells and ...

CAR2119’s single-infusion approach offers cost and compliance advantages, though its competitors maintain strong commercial ...

The embryo-like model could help scientists test new drugs, create stem cells for transplants and research blood disorders ...

The U.S. government has awarded Kernal Bio and three other sub-awardees up to $48 million to help advance the biotech’s in vivo mRNA-encoded CAR T-cell program. In an interesting—if not somewhat ...

The researchers argue that traditional vaccine development methods, which rely heavily on laboratory experimentation and long ...

The BioSpace 40 Under 40 winner opens up about his very personal career transformation from wealth management to biotech—and ...

This study offers a valuable methodological advance by introducing a gene panel selection approach that captures combinatorial specificity to define cell identity. The findings address key limitations ...

KYV-101 resulted in a profound reduction in disease-associated autoantibodies and impact on disease activity in patients with difficult-to-treat rheumatoid arthritis (RA) KYV-101 continues to demonstr ...